| Targets for ibrutinib beyond B cell malignancies A Berglöf, A Hamasy, S Meinke, M Palma, A Krstic, R Månsson, E Kimby, ... Scandinavian journal of immunology 82 (3), 208-217, 2015 | 133 | 2015 |
| Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases L Vargas, A Hamasy, BF Nore, CI E. Smith Scandinavian journal of immunology 78 (2), 130-139, 2013 | 90 | 2013 |
| Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant A Hamasy, Q Wang, KEM Blomberg, DK Mohammad, L Yu, M Vihinen, ... Leukemia 31 (1), 177-185, 2017 | 61 | 2017 |
| Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene KE Lundin, A Hamasy, PH Backe, LN Moens, E Falk-Sörqvist, ... Clinical Immunology 161 (2), 366-372, 2015 | 28 | 2015 |
| Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the … A Hussain, DK Mohammad, MO Gustafsson, M Uslu, A Hamasy, BF Nore, ... Journal of Biological Chemistry 288 (10), 7338-7350, 2013 | 19 | 2013 |
| Eleven percent intact PGM3 in a severely immunodeficient patient with a novel splice-site mutation, a case report KE Lundin, Q Wang, A Hamasy, P Marits, M Uzunel, V Wirta, AC Wikström, ... BMC pediatrics 18, 1-8, 2018 | 11 | 2018 |
| Effects of mutations in lymphoid malignancy and immunodeficiency disease AM Hamasy PQDT-Global, 2017 | | 2017 |
| Alamdar Hussain, Dara K. Mohammad1, Manuela O. Gustafsson1, Merve Uslu1, Abdulrahman BF Hamasy, AJ Mohamed, CIE Smith | | 2013 |
